¹û¶³Ó°Ôº

XClose

¹û¶³Ó°Ôº Department of Biochemical Engineering

Home
Menu

Vax Hub Platform Funding

Platform funding forms part of the Hub’s vision including knowledge transfer and ensuring that results translate to UK and LMIC vaccine markets.

Vax-Hub Feasibility Studies

In June 2020, the Vax-Hub launched a call for proposals for feasibility studies aligned to its aims and primarily of benefit to low- and middle-income countries (LMICs). We are pleased to announce that following our review process, seven projects were awarded funding.

PartnersProject title
Phenotypeca Ltd and University of OxfordÌýImproving VLP vaccine production from baker's yeast Ìý
University of Leeds and CPIÌýScale-up of bioproduction process in Pichia pastoris of a stabilised VLP vaccine candidate for poliomyeletisÌý
Vironova and ¹û¶³Ó°ÔºValidation of the MiniTEM system as an analytical quality control tool for vaccine and viral vector manufacturingÌý
University of TeessideÌý

The application of mass spectrometry approaches to profile, monitor and localise host cell protein products in adenovirus-based vaccine manufactureÌý

PT BioFarma and ¹û¶³Ó°ÔºÌý

Optimisation of upstream process for recombinant COVID-19 expressed in Pichia pastorisÌý

University of Oxford and ¹û¶³Ó°ÔºÌýCOVID-19 vaccine formulation Ìý

Vax-Hub Interaction Vouchers

In February 2020, the Vax-Hub launched a call for proposals for interaction vouchersÌýto support or encourage collaboration between its academic and industrial partners. We are pleased to announce that following our review process, six projects were awarded funding.Ìý

PartnersProject title
Hilleman Labs and ¹û¶³Ó°ÔºEstablishing the use of microscale chromatography-for downstream process optimization of Group B streptococcus polysaccharides
Phenotypeca Ltd and University of OxfordExploiting the genetic diversity of Saccharomyces cerevisiae for VLP production

Sartorius Stedim Biotech and University of Oxford

Cost of goods evaluation of adenovirus-based vaccine against Coronavirus
Sartorius Stedim Biotech and University of OxfordImproving scalability and productivity of an adenovirus-based vaccine against Coronavirus

Univercells, University of Leeds and ¹û¶³Ó°Ôº

Proof of principle synthesis of polio virus-like particles in an E. coli cell-free manufacturing platform
Vironova and ¹û¶³Ó°ÔºMiniTEM analysis: characterisation of Viral Vaccines, Vectors and VLPs

Vax-Hub membership

Platform funding has been awarded to members of the Vax-Hub Users Group only. If you are not currently a member of the Hub but would be interested in joining to access this and other Hub benefits, please contactÌývaxhub@ucl.ac.uk

Ìý

Ìý

Ìý